Probe • Vol LXII • No. 3 • May–Aug 2023 • 29 Effect of Liv.52 DS on Various Liver Parameters in Nonalcoholic Fatty Liver Disease hepatomegaly had also reduced from 90% to 61.33% (Figure). A significant improvement in abdominal discomfort due to hepatomegaly, fatigue, and weakness was also observed (Table 3). As per the cumulative data, at the end of the study, the NAFLD fibrosis score suggested no further progression to fibrosis. Some patients with indeterminate NAFLD score at baseline also showed slight improvements toward normalcy at the end of the study. No clinically significant adverse events were either observed or reported in the studies. Conclusion This cumulative analysis demonstrated that oral administration of Liv.52 DS tablets in patients with NAFLD, for 2 to 3 months, can cause significant symptomatic improvements; reduction in SGPT and SGOT levels; reduction in hepatomegaly; and a fibrosis-free state. The hepatoprotective, antioxidant, antimicrobial, antiviral, and anti-inflammatory actions of Liv.52 DS tablets can be attributed to its constituents that primarily include herbs such as Capparis spinosa, Terminalia arjuna, Cichorium intybus, Cassia occidentalis, Achillea millefolium, Solanum nigrum, and Tamarix gallica. Thus, it can be concluded that Liv.52 DS tablets are effective in the management of NAFLD, by improving various liver parameters. Table 2. Cumulative Analysis of SGOT Levels Patients, n Baseline End of Study P Value Mean ± SD Mean ± SD – 50 32.08 ± 4.62 29.25 ± 4.32 – 19 56.74 ± 31.77 39 ± 11.47 – 60 60.33 ± 13.04 54.12 ± 17.26 – 24 32.88 ± 17.06 28.18 ± 10.19 – 153 45.51 ± 16.62 37.64 ± 10.81 < .0001 SGOT, serum glutamic oxaloacetic transaminase. Table 3. Effect of Liv.52 DS Tablets on Signs and Symptoms of Nonalcoholic Fatty Liver Disease Abdominal Discomfort Due To Hepatomegaly Screening (n = 76) End of Study (n = 76) P Value Absent 0 (0%) 47 (62%) < .0001 Present 76 (100%) 29 (38%) Fatigue Screening (n = 53) End of Study (n = 53) Absent 0 (0%) 40 (75%) < .0001 Present 53 (100%) 13 (25%) Weakness Screening (n = 54) End of Study (n = 54) Absent 0 (0%) 34 (63%) < .0001 Present 54 (100%) 20 (37%) Fisher's exact test. Significance < .05. 90 100 70 50 20 10 38.66 90 61.33 10 30 Baseline End of Study 40 60 No Hepatomegaly (< 16 cm) Hepatomegaly (> 16 cm) 80 0 Percentage Table 1. Cumulative Analysis of SGPT Levels Patients, n Baseline End of Study P Value Mean ± SD Mean ± SD — 50 61.12 ± 10.51 41.08 ± 7.69 — 19 68.89 ± 21.25 45.56 ± 19.87 — 60 70.68 ± 18.49 61.9 ± 22.7 — 24 47.54 ± 24.61 38.72 ± 17.58 — 153 62.06 ± 18.72 46.82 ± 16.96 < .0001 SGPT, serum glutamic pyruvic transaminase. Figure. Effect of Liv.52 DS Tablets on Hepatomegaly Based on Ultrasonography Findings
RkJQdWJsaXNoZXIy MjAwNDg=